TRCT
QNCX icon

Tower Research Capital (TRC)’s Quince Therapeutics QNCX Stock Holding History

Tower Research Capital (TRC)’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$886 Sell
44
-31
-41% -$6.22K ﹤0.01% 4760
2025
Q4 		$50K Buy
75
+67
+838% +$33.7K ﹤0.01% 2412
2025
Q3 		$2.62K Buy
+8
New +$2.66K ﹤0.01% 4607
2025
Q1 		– Sell
-8
Closed -$3.17K – 5673
2024
Q4 		$3.17K Sell
8
-20
-71% -$6.01K ﹤0.01% 4695
2024
Q3 		$4.31K Sell
28
-20
-42% -$2.87K ﹤0.01% 4592
2024
Q2 		$7.21K Buy
48
+12
+33% +$2.17K ﹤0.01% 4484
2024
Q1 		$7.71K Buy
36
+2
+6% +$497 ﹤0.01% 4158
2023
Q4 		$7.09K Buy
+34
New +$6.81K ﹤0.01% 4660
2023
Q2 		– Hold
0
– – – 6299
2023
Q1 		– Hold
0
– – – 6192
2022
Q4 		– Sell
-41
Closed -$11K – 6275
2022
Q3 		$11K Buy
41
+19
+86% +$7.24K ﹤0.01% 4457
2022
Q2 		$9K Buy
22
+5
+29% +$3.53K ﹤0.01% 4578
2022
Q1 		$21K Sell
17
-14
-45% -$19.1K ﹤0.01% 3492
2021
Q4 		$79K Buy
31
+19
+158% +$116K ﹤0.01% 2394
2021
Q3 		$229K Sell
12
-10
-45% -$159K 0.01% 1690
2021
Q2 		$229K Buy
22
+8
+57% +$67.1K 0.01% 1817
2021
Q1 		$103K Sell
14
-11
-44% -$79.2K ﹤0.01% 2564
2020
Q4 		$138K Sell
25
-47
-65% -$416K ﹤0.01% 2052
2020
Q3 		$718K Buy
72
+60
+500% +$546K 0.01% 1297
2020
Q2 		$113K Buy
12
+10
+500% +$91.6K ﹤0.01% 2350
2020
Q1 		$15K Buy
+2
New +$19.7K ﹤0.01% 1843
2019
Q3 		– Sell
-2
Closed -$16K – 4443
2019
Q2 		$16K Buy
+2
New +$11.9K ﹤0.01% 2304

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tower Research Capital (TRC)'s QNCX Position: Q1 2026 in Review

Tower Research Capital (TRC) reduced its Quince Therapeutics (QNCX) stake by 41% in Q1 2026, selling an estimated $6.22K and leaving 44 shares worth $886. The position accounts for ﹤0.01% of the portfolio, ranked #4760.

Tower Research Capital (TRC) first reported a position in QNCX in Q2 2019 and has held it in 20 quarters since. The position peaked at $718K in Q3 2020. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Tower Research Capital (TRC) held 44 shares of Quince Therapeutics worth $886 as of Q1 2026.
  • Tower Research Capital (TRC) sold 31 Quince Therapeutics shares in Q1 2026, an estimated $6.22K.
  • Quince Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4760 holding.
  • Tower Research Capital (TRC) first reported a position in Quince Therapeutics in Q2 2019 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Quince Therapeutics position peaked at $718K in Q3 2020.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.